Announcements
- Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer
- Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
- Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology
- Akero Therapeutics Announces Pricing of Public Offering of Common Stock
- Akero Therapeutics Announces Proposed Public Offering of Common Stock
- Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study
- Akero Therapeutics to Present Topline Week 96 Results from Phase 2b HARMONY Study Investigating Efruxifermin in Patients with Pre-Cirrhotic MASH
- Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Akero Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program
More ▼
Key statistics
On Monday, Akero Therapeutics Inc (0K4:STU) closed at 18.20, 70.09% above the 52 week low of 10.70 set on Oct 27, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 18.20 |
---|---|
High | 18.20 |
Low | 18.20 |
Bid | 20.51 |
Offer | 20.81 |
Previous close | 18.38 |
Average volume | 0.00 |
---|---|
Shares outstanding | 69.15m |
Free float | 59.01m |
P/E (TTM) | -- |
Market cap | 1.53bn USD |
EPS (TTM) | -2.85 USD |
Data delayed at least 15 minutes, as of May 06 2024.
More ▼